Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Eli Lilly (LLY) to $1,023 from $1,028 and keeps an Overweight rating on the shares. The firm is adjusting its estimates to account for the most recent IQVIA trends and company commentary, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Groundbreaking Study on STX-478: A New Hope for Advanced Solid Tumors
- Eli Lilly’s Volenrelaxin Study Withdrawn: Implications for Investors
- Trump Trade: Trump Administration pursuing deals in range of industries
- Trump admin pursuing deals in range of industries, Reuters reports
- Closing Bell Movers: Bentley Systems up 5% on S&P MidCap 400 entry